Down-regulation of rat β-adrenoceptors by clenbuterol or desipramine does not require chronic treatment: [ 3H]CGP-12177 binding reveals rapid (24 hour) modulation
Desipramine (DMI, 15 mg/kg, s.c.) decreased [ 3H]CGP-12177-labelled cortical β-adrenoceptor density (B max) by 30% upon chronic (14 day) treatment. However, even a single dose (in mg/kg) of DMI (15) or the β-adrenoceptor agonist, clenbuterol (20), induced a rapid (24 hour) and significant reduction...
Gespeichert in:
| Veröffentlicht in: | Brain research bulletin 1996, Vol.41 (2), p.93-96 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 96 |
|---|---|
| container_issue | 2 |
| container_start_page | 93 |
| container_title | Brain research bulletin |
| container_volume | 41 |
| creator | Newman-Tancredi, A. Verrièle, L. Chaput, C. Millan, M.J. |
| description | Desipramine (DMI, 15 mg/kg, s.c.) decreased [
3H]CGP-12177-labelled cortical β-adrenoceptor density (B
max) by 30% upon chronic (14 day) treatment. However, even a single dose (in mg/kg) of DMI (15) or the β-adrenoceptor agonist, clenbuterol (20), induced a rapid (24 hour) and significant reduction of β-adrenoceptor B
max (−15%;
p |
| doi_str_mv | 10.1016/0361-9230(96)00150-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78459388</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0361923096001505</els_id><sourcerecordid>15681240</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2132-16c53dd0ddc2136b797686ef44bc36f315c3c4c2eed64b198aa06a865679bd083</originalsourceid><addsrcrecordid>eNqFkU9u1TAQhyMEKo_CDUDyAqF2EfCfxHa6QEIPaJEqwQJWCFmOPWmNEju1naKehxtwEM6Ew3t6S1hZo_lm_NN8VfWU4JcEE_4KM07qjjJ80vFTjEmL6_ZetSFSsJqKRtyvNgfkYfUope8YYy5bflQdSSk6Luim-vk2_PB1hKtl1NkFj8KAos7o969a2wg-GJhziAn1d8iM4PslQwwjChFZSG6OenIekA2QkA8ZRbhZXARkrmPwzqAcQecJfD5DXxG7-LY9_1QTSoRAvfPW-asycQt6TOXX2Vl0Qht0HZZ4iqZg95keVw-GQsCT_XtcfXn_7vP2or78eP5h--ayNpQwWhNuWmYttnateS86wSWHoWl6w_jASGuYaQwFsLzpSSe1xlxL3nLR9RZLdly92O2dY7hZIGU1uWRgHLWHsCQlZNN2TP4fJC2XhDa4gM0ONDGkFGFQc3STjneKYLVKVKshtRpSXSlWiaotY8_2-5d-AnsY2lsr_ef7vk5Gj0PU3rh0wBgt-v_GfL3DoBzt1kFUyTjwBmwxZLKywf07xx_jm7lq</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15681240</pqid></control><display><type>article</type><title>Down-regulation of rat β-adrenoceptors by clenbuterol or desipramine does not require chronic treatment: [ 3H]CGP-12177 binding reveals rapid (24 hour) modulation</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Newman-Tancredi, A. ; Verrièle, L. ; Chaput, C. ; Millan, M.J.</creator><creatorcontrib>Newman-Tancredi, A. ; Verrièle, L. ; Chaput, C. ; Millan, M.J.</creatorcontrib><description>Desipramine (DMI, 15 mg/kg, s.c.) decreased [
3H]CGP-12177-labelled cortical β-adrenoceptor density (B
max) by 30% upon chronic (14 day) treatment. However, even a single dose (in mg/kg) of DMI (15) or the β-adrenoceptor agonist, clenbuterol (20), induced a rapid (24 hour) and significant reduction of β-adrenoceptor B
max (−15%;
p<0.01). Acute treatment with amitryptiline (10), clorgyline (1), fluoxetine (10), nomifensine (10) or maprotiline (20) had no significant effect on [
3H]CGP-12177-labelled β-adrenoceptors, suggesting that rapid down-regulation may not be a general property of antidepressant drugs. None of the antidepressants altered the B
max of [
3H]ketanserin-labelled 5-HT
2A receptors on acute treatment. These results show that β-adrenoceptor down-regulation by clenbuterol and DMI is not dependent on chronic treatment and may, therefore, be a poor correlate of the gradual onset of therapeutic efficacy seen clinically with antidepressant drugs.</description><identifier>ISSN: 0361-9230</identifier><identifier>EISSN: 1873-2747</identifier><identifier>DOI: 10.1016/0361-9230(96)00150-5</identifier><identifier>PMID: 8879672</identifier><identifier>CODEN: BRBUDU</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>[ 3H]CGP-12177 ; Acute treatment ; Adrenergic beta-Agonists - pharmacology ; Adrenergic beta-Antagonists - pharmacokinetics ; Adrenergic Uptake Inhibitors - pharmacology ; Animals ; Antidepressive Agents, Second-Generation - pharmacology ; Biological and medical sciences ; Clenbuterol ; Clenbuterol - pharmacology ; Desipramine ; Desipramine - pharmacology ; Down-regulation ; Down-Regulation - drug effects ; Male ; Medical sciences ; Neuropharmacology ; Pharmacology. Drug treatments ; Propanolamines - pharmacokinetics ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Rats ; Rats, Wistar ; Receptors, Adrenergic, beta - biosynthesis ; Receptors, Adrenergic, beta - drug effects ; Receptors, Serotonin - biosynthesis ; Receptors, Serotonin - drug effects ; β-Adrenoceptor</subject><ispartof>Brain research bulletin, 1996, Vol.41 (2), p.93-96</ispartof><rights>1996</rights><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2132-16c53dd0ddc2136b797686ef44bc36f315c3c4c2eed64b198aa06a865679bd083</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/0361923096001505$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,4010,27900,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3227488$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8879672$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Newman-Tancredi, A.</creatorcontrib><creatorcontrib>Verrièle, L.</creatorcontrib><creatorcontrib>Chaput, C.</creatorcontrib><creatorcontrib>Millan, M.J.</creatorcontrib><title>Down-regulation of rat β-adrenoceptors by clenbuterol or desipramine does not require chronic treatment: [ 3H]CGP-12177 binding reveals rapid (24 hour) modulation</title><title>Brain research bulletin</title><addtitle>Brain Res Bull</addtitle><description>Desipramine (DMI, 15 mg/kg, s.c.) decreased [
3H]CGP-12177-labelled cortical β-adrenoceptor density (B
max) by 30% upon chronic (14 day) treatment. However, even a single dose (in mg/kg) of DMI (15) or the β-adrenoceptor agonist, clenbuterol (20), induced a rapid (24 hour) and significant reduction of β-adrenoceptor B
max (−15%;
p<0.01). Acute treatment with amitryptiline (10), clorgyline (1), fluoxetine (10), nomifensine (10) or maprotiline (20) had no significant effect on [
3H]CGP-12177-labelled β-adrenoceptors, suggesting that rapid down-regulation may not be a general property of antidepressant drugs. None of the antidepressants altered the B
max of [
3H]ketanserin-labelled 5-HT
2A receptors on acute treatment. These results show that β-adrenoceptor down-regulation by clenbuterol and DMI is not dependent on chronic treatment and may, therefore, be a poor correlate of the gradual onset of therapeutic efficacy seen clinically with antidepressant drugs.</description><subject>[ 3H]CGP-12177</subject><subject>Acute treatment</subject><subject>Adrenergic beta-Agonists - pharmacology</subject><subject>Adrenergic beta-Antagonists - pharmacokinetics</subject><subject>Adrenergic Uptake Inhibitors - pharmacology</subject><subject>Animals</subject><subject>Antidepressive Agents, Second-Generation - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Clenbuterol</subject><subject>Clenbuterol - pharmacology</subject><subject>Desipramine</subject><subject>Desipramine - pharmacology</subject><subject>Down-regulation</subject><subject>Down-Regulation - drug effects</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Propanolamines - pharmacokinetics</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Receptors, Adrenergic, beta - biosynthesis</subject><subject>Receptors, Adrenergic, beta - drug effects</subject><subject>Receptors, Serotonin - biosynthesis</subject><subject>Receptors, Serotonin - drug effects</subject><subject>β-Adrenoceptor</subject><issn>0361-9230</issn><issn>1873-2747</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU9u1TAQhyMEKo_CDUDyAqF2EfCfxHa6QEIPaJEqwQJWCFmOPWmNEju1naKehxtwEM6Ew3t6S1hZo_lm_NN8VfWU4JcEE_4KM07qjjJ80vFTjEmL6_ZetSFSsJqKRtyvNgfkYfUope8YYy5bflQdSSk6Luim-vk2_PB1hKtl1NkFj8KAos7o969a2wg-GJhziAn1d8iM4PslQwwjChFZSG6OenIekA2QkA8ZRbhZXARkrmPwzqAcQecJfD5DXxG7-LY9_1QTSoRAvfPW-asycQt6TOXX2Vl0Qht0HZZ4iqZg95keVw-GQsCT_XtcfXn_7vP2or78eP5h--ayNpQwWhNuWmYttnateS86wSWHoWl6w_jASGuYaQwFsLzpSSe1xlxL3nLR9RZLdly92O2dY7hZIGU1uWRgHLWHsCQlZNN2TP4fJC2XhDa4gM0ONDGkFGFQc3STjneKYLVKVKshtRpSXSlWiaotY8_2-5d-AnsY2lsr_ef7vk5Gj0PU3rh0wBgt-v_GfL3DoBzt1kFUyTjwBmwxZLKywf07xx_jm7lq</recordid><startdate>1996</startdate><enddate>1996</enddate><creator>Newman-Tancredi, A.</creator><creator>Verrièle, L.</creator><creator>Chaput, C.</creator><creator>Millan, M.J.</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>1996</creationdate><title>Down-regulation of rat β-adrenoceptors by clenbuterol or desipramine does not require chronic treatment: [ 3H]CGP-12177 binding reveals rapid (24 hour) modulation</title><author>Newman-Tancredi, A. ; Verrièle, L. ; Chaput, C. ; Millan, M.J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2132-16c53dd0ddc2136b797686ef44bc36f315c3c4c2eed64b198aa06a865679bd083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>[ 3H]CGP-12177</topic><topic>Acute treatment</topic><topic>Adrenergic beta-Agonists - pharmacology</topic><topic>Adrenergic beta-Antagonists - pharmacokinetics</topic><topic>Adrenergic Uptake Inhibitors - pharmacology</topic><topic>Animals</topic><topic>Antidepressive Agents, Second-Generation - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Clenbuterol</topic><topic>Clenbuterol - pharmacology</topic><topic>Desipramine</topic><topic>Desipramine - pharmacology</topic><topic>Down-regulation</topic><topic>Down-Regulation - drug effects</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Propanolamines - pharmacokinetics</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Receptors, Adrenergic, beta - biosynthesis</topic><topic>Receptors, Adrenergic, beta - drug effects</topic><topic>Receptors, Serotonin - biosynthesis</topic><topic>Receptors, Serotonin - drug effects</topic><topic>β-Adrenoceptor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Newman-Tancredi, A.</creatorcontrib><creatorcontrib>Verrièle, L.</creatorcontrib><creatorcontrib>Chaput, C.</creatorcontrib><creatorcontrib>Millan, M.J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Brain research bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Newman-Tancredi, A.</au><au>Verrièle, L.</au><au>Chaput, C.</au><au>Millan, M.J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Down-regulation of rat β-adrenoceptors by clenbuterol or desipramine does not require chronic treatment: [ 3H]CGP-12177 binding reveals rapid (24 hour) modulation</atitle><jtitle>Brain research bulletin</jtitle><addtitle>Brain Res Bull</addtitle><date>1996</date><risdate>1996</risdate><volume>41</volume><issue>2</issue><spage>93</spage><epage>96</epage><pages>93-96</pages><issn>0361-9230</issn><eissn>1873-2747</eissn><coden>BRBUDU</coden><abstract>Desipramine (DMI, 15 mg/kg, s.c.) decreased [
3H]CGP-12177-labelled cortical β-adrenoceptor density (B
max) by 30% upon chronic (14 day) treatment. However, even a single dose (in mg/kg) of DMI (15) or the β-adrenoceptor agonist, clenbuterol (20), induced a rapid (24 hour) and significant reduction of β-adrenoceptor B
max (−15%;
p<0.01). Acute treatment with amitryptiline (10), clorgyline (1), fluoxetine (10), nomifensine (10) or maprotiline (20) had no significant effect on [
3H]CGP-12177-labelled β-adrenoceptors, suggesting that rapid down-regulation may not be a general property of antidepressant drugs. None of the antidepressants altered the B
max of [
3H]ketanserin-labelled 5-HT
2A receptors on acute treatment. These results show that β-adrenoceptor down-regulation by clenbuterol and DMI is not dependent on chronic treatment and may, therefore, be a poor correlate of the gradual onset of therapeutic efficacy seen clinically with antidepressant drugs.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>8879672</pmid><doi>10.1016/0361-9230(96)00150-5</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0361-9230 |
| ispartof | Brain research bulletin, 1996, Vol.41 (2), p.93-96 |
| issn | 0361-9230 1873-2747 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78459388 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | [ 3H]CGP-12177 Acute treatment Adrenergic beta-Agonists - pharmacology Adrenergic beta-Antagonists - pharmacokinetics Adrenergic Uptake Inhibitors - pharmacology Animals Antidepressive Agents, Second-Generation - pharmacology Biological and medical sciences Clenbuterol Clenbuterol - pharmacology Desipramine Desipramine - pharmacology Down-regulation Down-Regulation - drug effects Male Medical sciences Neuropharmacology Pharmacology. Drug treatments Propanolamines - pharmacokinetics Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopharmacology Rats Rats, Wistar Receptors, Adrenergic, beta - biosynthesis Receptors, Adrenergic, beta - drug effects Receptors, Serotonin - biosynthesis Receptors, Serotonin - drug effects β-Adrenoceptor |
| title | Down-regulation of rat β-adrenoceptors by clenbuterol or desipramine does not require chronic treatment: [ 3H]CGP-12177 binding reveals rapid (24 hour) modulation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T21%3A27%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Down-regulation%20of%20rat%20%CE%B2-adrenoceptors%20by%20clenbuterol%20or%20desipramine%20does%20not%20require%20chronic%20treatment:%20%5B%203H%5DCGP-12177%20binding%20reveals%20rapid%20(24%20hour)%20modulation&rft.jtitle=Brain%20research%20bulletin&rft.au=Newman-Tancredi,%20A.&rft.date=1996&rft.volume=41&rft.issue=2&rft.spage=93&rft.epage=96&rft.pages=93-96&rft.issn=0361-9230&rft.eissn=1873-2747&rft.coden=BRBUDU&rft_id=info:doi/10.1016/0361-9230(96)00150-5&rft_dat=%3Cproquest_cross%3E15681240%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=15681240&rft_id=info:pmid/8879672&rft_els_id=0361923096001505&rfr_iscdi=true |